



Hemophilia B is the third most frequently reported (1/30,000 male 
neonates) congenital bleeding disorder in Poland [1]. Hemophilia 
B is a recessive, X-linked congenital bleeding disorder caused by the 
deficiency of clotting Factor IX (FIX) in plasma due to genetic mutations 
on the FIX gene. The main symptoms related to severe hemophilia 
B are bleeding into large joints, leading to the so-called hemophilic 
arthropathy, and disability of the musculoskeletal system. Hemophilia 
is also associated with bleeding into the temporomandibular joint 
(TMJ), causing their gradual degeneration and dysfunction, observed 
mainly in the form of ankylosis, along with various degrees of mandible 
movement limitations [2]. The type, severity, and frequency of intra- 
articular bleeding depend on the level of activity of the deficient clotting 
factor. There are three main types of hemophilia B: mild, moderate, 
and severe. Severe hemophilia B is diagnosed when the activity of FIX 
is < 1% [3] and is characterized by spontaneous bleeding into joints 
or muscles, predominantly in the absence of identifiable hemostatic 
challenge. A moderately severe form of the disease is sometimes 
diagnosed with an activity level of FIX ≤ 2%.
The cornerstone of hemophilia B therapy is the substitution of FIX. 
It can be applied as an episodic (“on demand”) treatment or 
as a regular continuous treatment (prophylaxis). The most 
serious complication of substitution treatment is the development of 
alloantibodies (inhibitors) to FIX, which occurs in about 1%-3% of 
hemophilia B patients and requires therapy with bypassing agents 
for the treatment of bleeding episodes [4]. Currently, the standard 
substitutive treatment for hemophilia B is based on two types of FIX 
concentrates, plasma derived and recombinant, obtained through 
genetic engineering techniques [5]. Hemostasis management should 
be planned for dental extraction or surgical procedures performed
 within the oral cavity of patients with severe hemophilia B; in addition, 
an hematologist should also be consulted and FIX substitution 
provided. Prophylaxis against bleeding related to other surgical or 
dental procedures also includes the use of antifibrinolytic agents, 
such as tranexamic acid and e-aminocaproic acid, both in the form 
of systemic and topical preparations [4, 6]. Other hemostatic agents, 
such as porcine absorbable gelatin sponges, collagen sponges, 
cellulose platelet gels, thrombin preparations or increasingly popular 
fibrin glues, available both in the dry and in the liquid form, can also 
be used as topical treatment to prevent hemorrhage [7].
Improved control of bleeding facilitated by efficient hemostatic 
treatment makes it possible for a wide range of surgical procedures 
to be performed in patients with hemophilia B without inhibitors, 
including aesthetic procedures within the field of oral surgery and 
implantology [8, 9]. This greater accessibility of aesthetic procedures 
increases not only the comfort but also the quality of life of patients 
with hemophilia.
The aim of this paper is to present the case of an implantoprosthetic 
rehabilitation performed in a patient with severe hemophilia B. The 
surgical procedures were performed after infusion of recombinant 
FIX (BAX 326) during the clinical surgery study. BAX 326 was 
registered in the European Union in 2014 under the trade name 
of Rixubis (http://www.ema.europa.eu/ema/index.jsp?curl=pages/ 
medicines/human/medicines/003771/human_med_001830. 
jsp&mid=WC0b01ac058001d124) for treating and preventing 
hemorrhage in patients suffering from hemophilia B in all age groups.
Case study
Patient S.D., a 45-year-old man with severe hemophilia B, reported 
to the dental office in March 2013 to replace teeth and to undergo 
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prosthetic reconstruction of the lower dental arch. The patient was 
enrolled into the Rixubis surgery clinical study, aimed at evaluating 
the hemostatic effectiveness and safety of the recombinant FIX 
concentrate Rixubis in patients with severe or moderately severe 
hemophilia B who undergo emergency or scheduled surgical 
operation, invasive diagnostic procedures, or dental procedures.
The patient was scheduled to have the root of tooth 45 extracted 
and to have implants introduced in locations corresponding to teeth 
35, 37, 46, and 44 (Fig. 1). After a period of 6 months, implant 
osseointegration and implant exposure were to be evaluated 
by pantomographic X-ray. This was to be followed by prosthetic 
reconstruction.
In March 2013, the clotting factor Rixubis was infused, and the root 
of tooth 45 was extracted under local anesthesia. The tooth socket 
was curetted, a gelatin sponge was placed (Spongostan), and the 
wound was sutured with dissolvable sutures. Proper hemostasis 
was obtained, with blood loss measuring approximately 2 ml. The 
patient was asked to rinse his mouth with tranexamic acid (Exacyl) 
preparation (10 ml every 6 hours), as well as to use oral tablets of 
Exacyl at a total dose of 2 g in two divided doses.
In October 2013, following the infusion of Rixubis at a dose sufficient 
to attain 130% FIX activity, the mucoperiosteal flaps were incised and 
detached, and two implants were inserted in the area surrounding 
teeth 35 and 37: one implant being 3.7 mm in diameter and 10 mm 
in length (tooth 35) and the second 3.2 mm in diameter and 10 mm 
in length (tooth 37). The wound was rinsed and closed off. The 
procedure was performed under local anesthesia. No drains were 
introduced. The blood loss anticipated prior to the procedure was 
7-10 ml. The true blood loss during the procedure was assessed at 
6 ml, 3 ml per tooth. No bleeding or inflammation was observed in 
the operated area in the patient during the postoperative period. In 
agreement with the study protocol, the patient received a daily dose 
of 4418 IU FIX for the next 13 days and until complete healing of the 
wound.
The next two implants were implemented a month later in November 
2013, with the FIX level up to 145%. The procedure was performed 
under local anesthesia. The mucoperiosteal flaps in the area 
surrounding teeth 46 and 44 were incised and detached, and two 
further implants were inserted: one with a diameter of 3.7 mm and 
length of 10 mm (tooth 46); and another with a diameter of 3.2 mm 
and length of 10 mm (tooth 44). The wound was rinsed and closed off. 
No drains were introduced. The anticipated blood loss was 7-10 ml. 
The true blood loss during the procedure was assessed as 6 ml, 3 ml 
per tooth. No bleeding or inflammation was observed in the operated 
area after the procedure. According to clinical study requirements, 
the patient received Rixubis (in daily doses of 4500 IU–5700 IU) 
for 8 days after surgery until complete healing of the wound was 
achieved. On the sixth and eighth days following the surgery, the 
hemostatic effectiveness of the factor was assessed as excellent. 
The patient came to the Maxillofacial Surgery Clinic once again in 
May 2014, 6 months after the final implantation procedure to have 
the implants inserted in the mandible at teeth 46, 44, 35, and 37. The 
patient had previously been prepared in the Hematology Department, 
where the tested FIX was infused. During the examination, the 
condition of the patient was determined as good, while the X-ray 
image revealed that implant healing was progressing as expected. 
After obtaining the results of the activated partial thromboplastin 
time (APTT) (30.4 seconds) and FIX activity (99%), the surgical 
procedure was initiated. The anticipated blood loss equaled 5-10 ml. 
The implants inserted in the area of teeth 46 and 44 were exposed, 
and healing screws were introduced with minimal blood loss (about 
1 ml). The whole procedure lasted 10 minutes. The procedure was 
performed under local anesthesia. No drains were placed. The 
Fig. 1. Orthopantomogram of patient S.D. before implantoprosthetic rehabilitation
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implants introduced in the areas of teeth 35 and 37 were inserted, 
also under local anesthesia, and healing screws were introduced.
The procedure lasted 14 minutes, and the blood loss reached about 
1 ml. No drains were placed in this case (Fig. 2). One dose of 
Rixubis was administered on an ambulatory basis the next day.
The effectiveness of Rixubis was evaluated as excellent in both 
cases. The procedures used to insert the implants in the mandible 
were uncomplicated, with no excessive bleeding: the blood loss was 
about 2 ml, and no additional doses of clotting factor were required. 
The patient did not report any adverse symptoms, and no additional 
medication was needed to be administered. After the procedure, the 
patient was transferred to the Hematology Department for further 
care. The patient had control visits every 6 months in the outpatient 
clinic, the last one being on January 2017. No adverse or unexpected 
symptoms related to the implants were recorded.
Discussion
The preparation of patients with hemophilia before surgical operations 
and dental procedures, particularly prior to implant and prosthetic 
rehabilitation, constitutes a significant clinical challenge not only for 
surgeons but also for dentists and hematology specialists. In the 
case of procedures intended to introduce dental implants, correct 
hemostasis is crucial for the proper course of the osseointegration 
process. Appropriate bleeding control is also an important factor in 
case of tooth extractions and other surgical procedures performed 
within the oral cavity. Preparing patients before surgical procedures 
associated with disrupting the soft tissue depends on the extent of 
the scheduled procedure, as well as the severity of hemophilia and 
the possible presence of inhibiting alloantibodies (inhibitors). As far 
as extensive dental procedures are concerned, it is recommended 
to check the FIX activity level before surgery, especially in severe 
hemophilia B cases. Patients with severe hemophilia may suffer from 
extensive hemorrhage following tooth extraction and other dental 
procedures, not only during but even 2-5 days after surgery [4].
The most important stage of the preparation for invasive surgeries 
in severe hemophilia B patients is the administration of proper 
doses of FIX on a standard basis. The required dose is calculated by 
multiplying the required increase in FIX activity by the body weight 
of the patient [10, 11]. For major surgeries, FIX levels should not 
fall below 80%-100% of normal until wound healing is achieved 
[11]. In the patient described herein, Rixubis study procedures 
required the drawing of a blood sample for the determination of FIX 
activity, followed by the administration of a loading dose of Rixubis 
sufficient to raise the level of FIX in plasma to at least 80%–100% of 
normal, as introduction of implants is qualified as major surgery. The 
required FIX units were calculated according to the following formula 
using the subject’s most recently determined, individual incremental 
recovery: Required units = body weight (kg) × desired rise in factor IX 
(%) (IU/ dl) × {reciprocal of observed recovery}.
After surgery, the targeted levels of FIX were 80%-100% until 
adequate wound healing was observed and then 30%-60% for at 
least another 7 days. Intraoperative and postoperative blood losses 
were measured at the end of each procedure and then compared 
with the estimated volume of the expected average and maximum 
blood loss, as predicted preoperatively by the operating surgeon. 
In the presented case, the true blood loss was always significantly 
lower than expected, and no drains were needed during surgery. In 
the case of our patient, the hemostatic effectiveness of Rixubis was 
judged as excellent at all studied time points and in all evaluated 
procedures. No side effects, particularly thrombotic events, were 
seen after the administration of Rixubis.
The available literature provides only a few reports on implant 
and prosthetic rehabilitation in patients with hemophilia B [8, 9]. 
Fig. 2. Orthopantomogram of patient S.D. after final implantation procedure
36
Acta Haematologica Polonica
This is because these patients undergo these procedures very 
rarely, due  to the fear of excessive bleeding and a reluctance to 
encounter the poorer intraoperative conditions connected with 
limited mandibular movement caused by temporomandibular joint 
ankylosis [8]. Significant blood loss into the surgical site hinders the 
course of implant osseointegration and impairs therapeutic results 
(primary and secondary stabilization), which increases the risk of the 
dental implants being lost.
The cases presented in existing literature concern patients with 
hemophilia A and with the moderate form of the disease [8, 9]. In 
both cases, the authors obtained satisfactory aesthetic results with 
little blood loss, both during the intraoperative and the postoperative 
periods. With regard to the present patient with severe hemophilia B, 
both aesthetic and functional results were satisfactory, with minimal 
intraoperative and postoperative bleeding.
In conclusion, the use of Rixubis, along with the use of appropriate 
local hemostatic therapy, in this severe hemophilia B patient enabled 
dental implantation without excessive blood loss, thus increasing 
the chance of proper implant healing as well as allowing for an 
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